Medical Nutrition in the Glucagon-Like Peptide-1 (GLP-1) Era: Protein Strategies, Micronutrient Monitoring, and Lean Mass Preservation

Apr 26, 2026Clinical nutrition ESPEN

Nutrition approaches with GLP-1 treatments: protein plans, vitamin monitoring, and keeping muscle mass

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Daily protein intakes of ≥1.2 g/kg may help preserve lean mass in individuals undergoing GLP-1-based obesity treatment.

GLP-1 receptor agonists and dual agents are associated with significant weight loss through appetite suppression and reduced energy intake.
Fat mass loss is the primary outcome, but there is also a clinically relevant reduction in absolute lean mass.
Micronutrient deficiencies are common in individuals with obesity and may worsen with reduced intake during therapy.
Proposed protein intake targets include ≥1.2 g/kg daily, with specific meal-wise targets to ensure adequate nutrient intake.
Monitoring of body composition and micronutrient status is recommended, especially in high-risk patients.

AI simplified

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agents produce substantial, sustained weight loss primarily by suppressing appetite and lowering ad libitum energy intake. While fat mass loss predominates, randomized trials with body-composition substudies indicate a clinically relevant reduction in absolute lean mass. Concurrently, baseline micronutrient inadequacies are common in people with obesity and may be exacerbated by reduced intake, nausea, or vomiting during therapy. This narrative review synthesizes evidence on energy/macronutrient dynamics, body-composition outcomes, and guideline-informed protein targets to present a practical, dietitian-led framework for care. We propose pragmatic energy floors to preserve micronutrient adequacy; daily protein intakes of ≥1.2 g/kg (up to 1.6 g/kg in appropriate adults without chronic kidney disease (CKD)) with meal-wise targets of ∼0.3-0.4 g/kg and ∼2.5-3 g leucine; a structured laboratory panel (vitamin D, B12, iron studies, folate, zinc, and thiamine in high-risk patients); and integration of progressive resistance training. We also outline monitoring schedules using dual-energy X-ray absorptiometry (DXA)/bioelectrical impedance analysis (BIA) and adaptations for special populations (older adults, type 2 diabetes, CKD, vegetarian/vegan, sarcopenic obesity). The goal is to preserve lean mass, prevent deficiencies, and optimize outcomes of GLP-1-based obesity pharmacotherapy.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Medical Nutrition in the Glucagon-Like Peptide-1 (GLP-1) Era: Protein Strategies, Micronutrient Monitoring, and Lean Mass Preservation

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief